EPS

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

The industrial giant posted strong 2025 results and a cautious 2026 outlook, banking on its execution strategy and key acquisitions in high-growth markets.

Investors eye Globus Medical's upcoming report for a full-year look at its NuVasive integration, market trends, and a pivotal 2025 performance.

Brazil's fintech leader reports a record R$5.2B adjusted net income for 2025, outlining a strategy that pairs AI with human advisors to win the market.

With results expected to beat guidance, all eyes are on Progyny's upcoming earnings as a key indicator for the rapidly expanding corporate family-building industry.

VisionWave Holdings is leveraging a breakthrough in non-line-of-sight detection to compete for a piece of the Pentagon's new $13.4 billion autonomy budget.

As AI pushes data centers to their limits, the optical industry gathers at OFC 2026 to unveil the power-efficient, high-speed networks of the future.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

Networking giant Belden reports record 2025 revenue and profit while launching a major strategic overhaul to dominate the converging IT and OT markets.

Restaurant Brands International reports strong 2025 results, fueled by booming international sales, but faces headwinds with Popeyes' slump and BK franchisee pressures.

The snack giant outpaced the market in 2025 with its core brands, but projects a dip in 2026 earnings despite growth plans and a new buyback program.

Entergy posts strong 2025 earnings and eyes major growth, driven by a surge in demand from data centers and massive new infrastructure projects.

The insurer's double-digit dividend hike follows a year of record core earnings, rewarding shareholders and showcasing its robust financial health.

Data engine Cribl surpasses $300M in recurring revenue, positioning its open architecture as the essential plumbing for enterprises drowning in AI data.

As BJ’s prepares to report Q4 results, investors are watching if a pizza relaunch and new efficiencies can overcome industry-wide cost pressures.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

With its Q4 and full-year 2025 earnings release imminent, Ingevity faces investor scrutiny over its recent strategic divestitures and market position.

For the seventh year, General Mills is one of America's most responsible companies. We explore the data, public trust, and strategy behind this major ESG achievement.

Rapid7's 2026 awards reveal a shift in cybersecurity, where partners are no longer just resellers but crucial allies in the global, AI-driven fight.